Abingworth's early action
Why cancer company Tizona falls into Abingworth's sweet spot
Abingworth's venture deal flow in the past 12 months reveals a clear preference for getting in early on companies that are generating pipelines of first- or best-in-class products. The latest biotech to match the profile is
